Save up -80% on Rimonabant
Note: this is a drug discount program, not an insurance plan.
2018 Price of Rimonabant
* price without discount in nearest pharmacy. Price may vary.
We offer free Rimonabant coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Rimonabant every time. What are you waiting for? Claim your prescription drug card now!
Rimonabant volume of distribution
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Rimonabant
Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.
Rimonabant mechanism of action
Rimonabant is a specific CB1 cannabinoid receptor antagonist. There is considerable evidence that the endocannabinoid (endogenous cannabinoid) system plays a significant role in appetitive drive and associated behaviours. It is therefore reasonable to hypothesize that the attenuation of the activity of this system would have therapeutic benefit in treating disorders that might have a component of excess appetitive drive or over-activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders.
Dosage forms of Rimonabant
|Film-coated tablet||Oral use||20 mg|
Humans and other mammals
Indication of Rimonabant
For use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/msup2/sup, or patients wih a BMI greater than 27 kg/msup2/sup with associated risk factors, such as type 2 diabetes or dyslipidaemia.
Toxicity of Rimonabant
Almost twice as many people discontinued rimonabant compared with placebo because of adverse events (13.8% vs. 7.2%). These consistently involved psychiatric disorders (8.5% vs. 3.2%), including depression and anxiety. Other common side effects included insomnia, nausea, vomiting, diarrhoea and fatigue.
RX24 Drugs Disclaimer: before buying a Rimonabant on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.